12^th Annual Conference on Nephrology & Urology July 06-07, 2017 Seri Pacific Hotel, Kuala Lumpur, Malaysia

Biography:

Dr. R. Oettmeier had his medical studying at the Friedrich-Schiller-University Jena Germany.From 1993 – 2014 he worked in his own outpatient department with the focus on reflex therapies (Chirotherapy, Acupuncture, Neural Therapy), Homeopathy and special pain treatment and as leading head physician in the Clinic im LEBEN at Greiz, Germany. Since 2014 he is leading Doctor at the Paracelsus Clinic Lustmühle, Switzerland, a Comprehensive Center for Biologic-Integrative Medicine and Dentistry. He realizes considerable activities of seminars and presentations in the fields of Biological Medicine, is author of textbooks and publications in CAM, and finally of some guidebooks for patients. 

Abstract:

Additional to conventional basics, complementary and alternative medicine (CAM) also uses evidence-based aspects from environmental medicine (toxins, physical irritating fields), the vegetative nervous system (reflex zones, sympathetic-parasympathetic balance, somatotopies, odontomas), energetic medicine (acupuncture meridians of TCM, chakras from Ayurvedic medicine) as well as approved psycho-mentally and psycho-emotionally relationships. The uro-nephrological system is clearly embedded in this holistic context, which enables a clear diagnostic strategy to develop an individual therapeutic concept. With the usage of this thinking it is possible to treat the deep reasons of the diseases even more. Mostly, it is necessary to reduce the environmental toxic load, to optimize the dental situation and to diminish chronic neuro-modulative triggers (foci) with the help of neural therapy. Next, we pay attention to the intestinal health and immune system. Finally, the patient’s own healing forces were activated by using a big palette of natural remedies and organ cell therapy. The examples of chronic cystitis, nephrotic syndrome and prostate cancer illustrate the successful application of CAM in this fields.

Biography:

Michael D Wagener has received a Medical Degree from the University of Berlin, Germany, in 1991. During his Post-graduate training, he was trained in General Internal Medicine, Pneumology and Allergology in Davos (Switzerland). He received board certification in General Internal Medicine, Allergology and Pharmaceutical Medicine and Neuraltherapy. In 1997, he joined Eli Lilly as a Clinical Research Physician, in 2005 Novartis Pharma in Basel and in 2009 he became Chief Medical Officer of AC Immune in Lausanne (Switzerland). Since 2000, he was a member of the Executive Board of the Swiss Association of Pharmaceutical Medicine (SGPM) and in 2002 to 2008 he was elected President of this Organization. Since 2010, he is the Owner of an “Antiaging and Complementary Medicine Center” in Basel.

Abstract:

Phosphatidylcholine is a phospholipid that is one of the main components of lecithin. Lecithin is found in all cell membranes and plays a major role in maintaining the fluidity of the cell by affecting what enters and leaves the cell through the cell membrane. Given as infusion, PC might improve many conditions, among them kidney function and overall energy. Clinical studies have been performed in glomerulonephritis, where a reduction of edema could be observed. Also in renal insufficiency patients showed an increase in creatinine, urine volume and renal clearance when receiving PC intravenously. Overall patients suffering from fatigue from various causes (e.g. chronic kidney disease) were benefiting from phosphatidylcholine infusions. Standard toxicological assessments indicate no significant acute or chronic toxicity from PC, as well as no mutagenicity and no teratogenicity. 

Biography:

Maria Teresa Parisotto obtained the Nursing Diploma in 1974 and the Nursing Management Diploma in 1976, at the Nursing School Ospedale San Carlo, Milan, Italy.

At the beginning of her career she worked as Nurse Manager in a Dialysis Unit, Ospedale San Paolo, Milan, Italy.

In 1980 she left the hospital and started to work as Application Specialist first, Marketing Director Peritoneal Dialysis afterwards in Fresenius Medical Care Italy.

In 1999 she moved to Fresenius Medical Care headquarters (Bad Homburg, Germany) as Director Peritoneal Dialysis for Europe, Middle East and Africa.

From 2006 till 2016 she worked in Fresenius Medical Care Deutschland GmbH – NephroCare Coordination, Bad Homburg, Germany as Director Nursing Care Management for Europe, Middle East and Africa. Currently she is working Fresenius Medical Care Deutschland GmbH – Care Value Management, as Chief Nurse Advisor.
Her main areas of interest and experience are Vascular Access Cannulation and Care, Hygiene and Infection Control,  Dialysis processes analysis, Safety in Dialysis.

Her publications focused on Peritoneal Dialysis, Haemodialysis safety and quality and Vascular Access cannulation and care.

She participated in scientific projects with EDTNA/ERCA as co-author for the development of “Environmental Guidelines for Dialysis – A practical Guide to Reduce the Environmental Burden of Dialysis”, Co-Editor for the development of “Vascular Access Cannulation and Care – A Nursing Best Practice Guide for Arteriovenous Fistula” and editor of the “Vascular Access Cannulation and Care – A Nursing Best Practice Guide for Arteriovenous Graft”.

Abstract:

Introduction and Aim of the study

·       There is a close link between the availability of a well-functioning vascular access and patient survival on haemodialysis

·       Every effort should be made to maintain the functionality of the vascular access for long-term use.

·       Practices of access cannulation vary from clinic to clinic, mainly for historical reasons.

·       The aim of this study is to investigate the impact of cannulation technique on the survival of the arteriovenous fistula (AVF) and grafts (AVG).

 

Methods

In April 2009, a cross sectional survey was conducted in 171 dialysis units located in Europe, Middle East and Africa to collect details on vascular access cannulation practices.

On the basis of this survey¹, a cohort of patients was selected for follow-up, inclusion being dependent on the availability of corresponding access survival/intervention data in the clinical database. 

Access survival was analyzed using the Cox regression model (adjusted for within country effects) defining as events the need for first surgical access survival intervention.

Patients were censored for transplantation, death, loss of follow-up, or end of the study period (March 31, 2012). Results were adjusted for age, gender and diabetes mellitus

 

Results

Out of the 10,807 patients enrolled for the original survey, access survival data was available for 7,058 (65%) of patients,  these residing in Portugal, UK, Italy, Turkey, Romania, Slovenia, Poland and Spain.

Mean age was 63.5+15.0 years; 38.5% were female; 27.1% were diabetics; 90.6% had a native fistula and 9.4% had a graft. Access location was distal for 51.2% of patients. During the follow-up, 51.1% were treated with antiaggregants and 2.8% with anti-coagulants.

Prevalent needle sizes were 15 G and 16 G for 63.7% and 32.2% of the patients, respectively (14 G: 2.7%, 17 G: 1.4%). Cannulation technique was area for 65.8% and rope-ladder for 28.2%, and the direction of puncture was antegrade for 57.3%. Median blood flow was 350-400 mL/min.

 

Conclusions

The study revealed that area cannulation technique, despite being the most commonly used, was inferior to both rope-ladder and buttonhole for the maintenance of Vascular Access functionality.

With regard to the effect of needle and bevel direction, the combination of antegrade position of arterial needle with bevel up or down was significantly associated with better access survival than retrograde positioning with bevel down.

There was an increased risk of access failure for graft versus fistula, proximal vs distal location, right arm vs left arm, and the  presence of a venous pressure greater than 150 mmHg. The higher HR associated with a venous pressure greater than 150 mmHg should open a discussion on currently accepted limits

 

Biography:

Upon completion of Medical Degree and further specialization in General Surgery Dr. Dmitry Klokol proceeded with PhD in Surgery in Institute of Emergency and Reconstructive Surgery and postdoctoral study in the field of Regenerative medicine and Cell therapy. He has vast clinical, academical and research experience in surgery, anti-aging, regenerative, complementary medicine and cell therapy. He has published more than 50 articles, 2 books and is a member of the editorial board in one of American journals. At present he is Head of Medical Advisory Board in International Biomolecular research Company and Medical Director of European Wellness Centers.

Abstract:

Management of early andropause is one of the important issues in andrology. Early or premature andropause is associated with such symptoms as loss of libido and morning penile erection, erectile dysfunction, demonstration of low testosterone levels, and ultimately male infertility. Needless to mention that reduction of sexual hormonal expression plays a pivotal role in aging process. Genetics, previous illnesses, certain medical procedures, and environmental factors are the leading etiologic factors of premature andropause development.

Premature andropause is often responsible for cognitive decline, dyslipidemia, diabetes, obesity, fatigue, and loss of muscle bulk. Biochemical signs of premature andropause are reduction of basal and free testosterone levels at 15% or more below normal range.

Conventionally this condition is treated with testosterone replacement therapy. However, testosterone replacement may carry risk of cardiac hypertrophy, prostate hyperplasia and aggravate symptoms in men with prostate cancer.  

The objective of this study was to assess efficacy of biohormonal therapy using a combination of organ-specific peptides-extracts (Mito Organelles™, SBI, MF+, Germany) from hypothalamus, pituitary gland, adrenals, testicles and liver as a safer alternative to the testosterone replacement. The duration of the treatment is 4 months and does not require continuous prolonged drug intake. Organ-specific peptide therapy has high efficacy rate with no adverse reactions observed. Most of the patients had dramatic improvement of symptoms and increase of testosterone levels. None of the observed patients had need in further testosterone replacement.

Obtained preliminary results are promising and such therapeutic approach needs further studies and evaluation of late results and outcomes.

Biography:

Dr. Elayne Ooi is a Consultant Urologist who underwent her surgical training in Western Australia. She is a fellow of the Royal Australasian College of Surgeons and Society of Robotic Surgery. Previous appointments include being the Robotic Surgery and Oncology Fellow at Royal Adelaide Hospital.  She holds a Diploma of Surgical Anatomy and is an accredited instructor of the EMST Emergency Management of Severe Trauma course and regular instructs surgical workshops. Currently working as a general urologist, she has a special interest in brachytherapy and minimally invasive robotic surgery for prostate and kidney cancer.

Abstract:

SpaceOAR Space Organ At Risk is an absorbable injectable hydrogel which creates a temporary barrier between the prostate and rectum. It is used in patients undergoing local radiotherapy for prostate cancer. Traditionally, the dose-limiting factor for brachytherapy has been the rectum - due to the sensitive rectal mucosas close anatomical proximity to the prostate.

After being injected into the peri-rectal potential space under rectal ultra-sound guidance, SpaceOAR creates a hydrogel barrier pushing the rectum out of the way and forming a physical barrier. Clinically, this translates into reducing rectal radiation, rates of rectal toxicity and potentially allowing for an increased radiation dose to the posterior aspect of the prostate.

Made of polyethylene glycol, the hydrogel is formed when the accelerator and precursor are combined. Once injected into the peri-rectal space, it is immediately effective and remains so for 3 months. Over the space of 6 months, it is slowly absorbed and excreted by the kidneys.

Twenty-three patients with T1-T2 prostate cancer underwent spaceOAR insertion between 2014-2017 prior to prostate external beam radiotherapy. We will be presenting the short-term outcomes of SpaceOAR in this pilot study.

Biography:

Prof. Halim is  Professor of Pediatrics at Lincoln University College, Petaling Jaya, Malaysia and is  Consultant Pediatrician at KPJ Ampang Puteri Specialist Hospital. He was formerly Director of the Reproductive Research Centre, the National Population and Family Development Board, the Prime Minister’s Department (1985-1990). His research interest include cholestatic jaundice in infancy, developmental and behavioral problems of childhood, cellular and molecular medicine.  He is currently active in  research on fetal precursor stem cells since 2006  for the treatment of medical conditions untreatable in mainstream medicine  and on the use of eco-ultrafiltrates for  treatment of genetic and chromosomal abnormalities in children.  He  is currently  senior medical consultant/scientist to Fetal Cell Technologies  International and  is the author of 4 books on child health and 3 books on Live cell therapy the latest titled “Hope for untreatable medical conditions. Live cell therapy explained” (currently in print in the UK).    

Abstract:

The key to preventing kidney diseases is in maintaining the body regulatory mechanisms in an optimum physiological state.  Cellular functions are sensitive to the state of the EXTRACELLULAR  MATRIX.  Genetic and epigenetic factors interact in a myriad of ways  to control cell phenotype through cell-matrix interactions thereby leading to a healthy or disease state.   Each patient is unique in his/her physical, mental,  social and psychospiritual domains,  his environment and  his lifestyle.  The  world we live in has changed so much with  unprecedented environmental degradation,  pollution, agricultural food production methods,  xenobiotics in  animal husbandry and endocrine disrupting chemicals,  all contributing  to  dysfunctions in our body regulatory systems. The unbalanced external ecological system reflects  itself in our own inner ecosystem,  disrupting our immunological, endocrine and  neurological systems.  All these compounded by emotional and physical stresses  lead to  poorer  cellular health and vitality.  The objective of  classical cell therapy has always been the enfreshment/restoration of the functional capability of the cells and their functional associates, the tissues and organs. It aims at producing a state of health thereby eliminating symptoms.  In the Genomic era today, we see the possibility of using genomics,  epigenomics,  transcriptomics, proteomics, metabolomics, microbiomics (multi  -omics) to  provide biomarkers for prevention, ill health and healing.  This is an exciting  scientific development.  A more integrative approach to medicine  and research  is imperative where positive outcomes of treatment are studied in the  context of systems biology to find ways to correct the identifiable pathway perturbations thereby leading to  treatment.  The speaker will discuss management  of kidney disorders with fetal precursor stem cell transplantation and the preparatory protocol to achieve the best possible state of the  extracellular matrix.  He will touch on the  role of microbiome, nutrients, lifestyle, environmental  and psychospiritual factors in influencing phenotypic expression through epigenetic mechanisms.

Biography:

Prof. Halim is  Professor of Pediatrics at Lincoln University College, Petaling Jaya, Malaysia and is  Consultant Pediatrician at KPJ Ampang Puteri Specialist Hospital. He was formerly Director of the Reproductive Research Centre, the National Population and Family Development Board, the Prime Minister’s Department (1985-1990). His research interest include cholestatic jaundice in infancy, developmental and behavioral problems of childhood, cellular and molecular medicine.  He is currently active in  research on fetal precursor stem cells since 2006  for the treatment of medical conditions untreatable in mainstream medicine  and on the use of eco-ultrafiltrates for  treatment of genetic and chromosomal abnormalities in children.  He  is currently  senior medical consultant/scientist to Fetal Cell Technologies  International and  is the author of 4 books on child health and 3 books on Live cell therapy the latest titled “Hope for untreatable medical conditions. Live cell therapy explained” (currently in print in the UK).    

Abstract:

The key to preventing kidney diseases is in maintaining the body regulatory mechanisms in an optimum physiological state.  Cellular functions are sensitive to the state of the EXTRACELLULAR  MATRIX.  Genetic and epigenetic factors interact in a myriad of ways  to control cell phenotype through cell-matrix interactions thereby leading to a healthy or disease state.   Each patient is unique in his/her physical, mental,  social and psychospiritual domains,  his environment and  his lifestyle.  The  world we live in has changed so much with  unprecedented environmental degradation,  pollution, agricultural food production methods,  xenobiotics in  animal husbandry and endocrine disrupting chemicals,  all contributing  to  dysfunctions in our body regulatory systems. The unbalanced external ecological system reflects  itself in our own inner ecosystem,  disrupting our immunological, endocrine and  neurological systems.  All these compounded by emotional and physical stresses  lead to  poorer  cellular health and vitality.  The objective of  classical cell therapy has always been the enfreshment/restoration of the functional capability of the cells and their functional associates, the tissues and organs. It aims at producing a state of health thereby eliminating symptoms.  In the Genomic era today, we see the possibility of using genomics,  epigenomics,  transcriptomics, proteomics, metabolomics, microbiomics (multi  -omics) to  provide biomarkers for prevention, ill health and healing.  This is an exciting  scientific development.  A more integrative approach to medicine  and research  is imperative where positive outcomes of treatment are studied in the  context of systems biology to find ways to correct the identifiable pathway perturbations thereby leading to  treatment.  The speaker will discuss management  of kidney disorders with fetal precursor stem cell transplantation and the preparatory protocol to achieve the best possible state of the  extracellular matrix.  He will touch on the  role of microbiome, nutrients, lifestyle, environmental  and psychospiritual factors in influencing phenotypic expression through epigenetic mechanisms